I also have a better understanding now of the distribution of Phase II and Phase III trials amongst the different types of cancer ( see https://hotcopper.com.au/posts/41596009/single ).
This means that I can update the summary table.
See chart integrated into the table below - to highlight just how much Phase II and III data there is.
That's an incredible asset for a microcap biotech (MCAP $15M as at 22 November 2019), particularly given the theoretical revenue potential.
Theoretical Revenue Potential of RACE Oncology 5-path Strategy, page-58
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |